$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc

$fenc Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000114420414031132 Filed on May 15, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$510.0K	$360.0K
YoY Change	41.67%	12.5%
% of Gross Profit
Research & Development	$24.00K	$178.0K
YoY Change	-86.52%	-39.86%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$24.00K	$178.0K
YoY Change	-86.52%	-39.86%
Operating Profit	-$537.0K	-$537.0K
YoY Change	0.0%	-12.82%
Interest Expense	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$2.657M	-$3.571M
YoY Change	-25.6%	-207.21%
Pretax Income	-$3.190M	-$4.110M
YoY Change	-22.38%	-251.1%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.194M	-$4.108M
YoY Change	-22.25%	-251.31%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.33
Diluted Earnings Per Share	-$0.33	-$489.9K
COMMON SHARES
Basic Shares Outstanding	9.769M shares	25.16M shares
Diluted Shares Outstanding	9.769M shares	25.16M shares

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.340M	$1.900M
YoY Change	-29.47%	-59.75%
Cash & Equivalents	$1.338M	$1.896M
Short-Term Investments
Other Short-Term Assets	$3.000K	$40.00K
YoY Change	-92.5%	185.71%
Inventory
Prepaid Expenses	$54.00K
Receivables
Other Receivables
Total Short-Term Assets	$1.400M	$1.940M
YoY Change	-27.84%	-59.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	-$5.000K	$0.00
YoY Change		-100.0%
TOTAL ASSETS
Total Short-Term Assets	$1.400M	$1.940M
Total Long-Term Assets	-$5.000K	$0.00
Total Assets	$1.395M	$1.940M
YoY Change	-28.09%	-59.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$154.0K	$700.0K
YoY Change	-78.0%	87.17%
Accrued Expenses	$57.00K	$90.00K
YoY Change	-36.67%	136.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.729M	$11.00M
YoY Change	-47.92%	409.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.729M	$11.00M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$5.729M	$11.00M
YoY Change	-47.92%	408.79%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$106.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.334M	-$9.065M
YoY Change
Total Liabilities & Shareholders Equity	$1.395M	$1.940M
YoY Change	-28.09%	-59.22%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$3.194M	-$4.108M
YoY Change	-22.25%	-251.31%
Depreciation, Depletion And Amortization	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$378.0K	-$407.0K
YoY Change	-7.13%	-29.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00	$0.00
YoY Change
Cash From Financing Activities	$53.00K	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-$378.0K	-$407.0K
Cash From Investing Activities	$0.00	$0.00
Cash From Financing Activities	$53.00K	$0.00
Net Change In Cash	-$325.0K	-$407.0K
YoY Change	-20.15%	-29.58%
FREE CASH FLOW
Cash From Operating Activities	-$378.0K	-$407.0K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$378.0K	-$407.0K
YoY Change	-7.13%	-29.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the opinion of management, these unaudited interim condensed financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company’s financial position at March 31, 2014, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1243000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	212000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1243000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-4334000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	81000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-378000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87625000	USD
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	5517000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1404000	USD
CY2013Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2014Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	1187000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4379000	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	111892000	USD
CY2014Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1333000	USD
CY2013Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1635000	USD
CY2014Q1	us-gaap	Cash Cash	5000	USD
CY2014Q1	us-gaap	Cash Cash	2000	CAD
CY2013Q4	us-gaap	Cash Cash	28000	USD
CY2013Q4	us-gaap	Cash Cash	39000	CAD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1338000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1663000	USD
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	54000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8000	USD
CY2014Q1	us-gaap	Assets Assets	1395000	USD
CY2013Q4	us-gaap	Assets Assets	1752000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	154000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	57000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	132000	USD
CY2014Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5518000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2863000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	5729000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3207000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	66790000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	66790000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39525000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39210000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	108698000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-1455000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1395000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1752000	USD
CY2013Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-3573000	USD
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-2655000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22035000	shares
CY2014Q1	adhxf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	1.44
CY2014Q1	adhxf	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerms	P1Y3M18D
CY2010Q2	adhxf	Percentage Of Common Shares Outstanding PercentageOfCommonSharesOutstanding	0.25	pure
CY2013Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	USD
CY2014Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	262000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0220	pure
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.37	pure
CY2014Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1338000	USD
CY2014Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	6855000	USD
CY2013Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29308000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29158000	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29308000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29158000	shares
CY2013Q1	us-gaap	Revenues Revenues	0	USD
CY2014Q1	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	178000	USD
CY2014Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69797000	USD
CY2013Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	386000	USD
CY2013Q1	adhxf	Gain On Deferred Lease Inducements GainOnDeferredLeaseInducements	0	USD
CY2014Q1	adhxf	Gain On Deferred Lease Inducements GainOnDeferredLeaseInducements	0	USD
	adhxf	Gain On Deferred Lease Inducements GainOnDeferredLeaseInducements	497000	USD
CY2013Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2014Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	13094000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	359000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	505000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33933000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-537000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-537000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-116713000	USD
CY2013Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2014Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1283000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	19000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4379000	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	256000	USD
CY2013Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000	USD
CY2014Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	-2000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2897000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3571000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2657000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6230000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-4108000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-3194000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-110483000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25158000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29308000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25158000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29308000	shares
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3573000	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2655000	USD
CY2013Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
CY2014Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
CY2013Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2014Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	544000	USD
CY2014Q1	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0	USD
	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	35000	USD
CY2013Q1	adhxf	Amortization Of Tenant Inducements Received AmortizationOfTenantInducementsReceived	0	USD
CY2014Q1	adhxf	Amortization Of Tenant Inducements Received AmortizationOfTenantInducementsReceived	0	USD
	adhxf	Amortization Of Tenant Inducements Received AmortizationOfTenantInducementsReceived	412000	USD
CY2013Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-36000	USD
CY2013Q1	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
CY2014Q1	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
	us-gaap	Severance Costs1 SeveranceCosts1	168000	USD
CY2013Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	129000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1202000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	133000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10464000	USD
CY2013Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-128000	USD
CY2014Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	101000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	292000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-407000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1440000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	115000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	0	USD
	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	24000	USD
CY2013Q1	adhxf	Withdrawals From Restricted Cash WithdrawalsFromRestrictedCash	0	USD
CY2014Q1	adhxf	Withdrawals From Restricted Cash WithdrawalsFromRestrictedCash	0	USD
	adhxf	Withdrawals From Restricted Cash WithdrawalsFromRestrictedCash	190000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	209000	USD
CY2013Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2014Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	22148000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	22791000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	166000	USD
CY2013Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2014Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	640000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1483000	USD
CY2013Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2014Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	68000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	65000	USD
CY2003	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2004	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000	USD
CY2000	adhxf	Equity Rights Offering EquityRightsOffering	171000	USD
CY2004	adhxf	Stock Issued During Period Value Merger StockIssuedDuringPeriodValueMerger	-22000	USD
CY2003	us-gaap	Dividends Cash DividendsCash	158000	USD
CY1999	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	20000	USD
CY2001	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	182000	USD
CY2002	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	11000	USD
CY2003	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-159000	USD
CY2004	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-219000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1392000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8000	USD
CY2013Q1	adhxf	Proceeds From Issuance Of Commonstock Net O Fexpenses ProceedsFromIssuanceOfCommonstockNetOFexpenses	0	USD
CY2014Q1	adhxf	Proceeds From Issuance Of Commonstock Net O Fexpenses ProceedsFromIssuanceOfCommonstockNetOFexpenses	53000	USD
	adhxf	Proceeds From Issuance Of Commonstock Net O Fexpenses ProceedsFromIssuanceOfCommonstockNetOFexpenses	88066000	USD
CY2013Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	465000	USD
CY2013Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3017000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	87000	USD
CY2013Q1	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90068000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	378000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-407000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-325000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1338000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2303000	USD
CY1996Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1896000	USD
CY2004Q4	us-gaap	Stockholders Equity StockholdersEquity	16654000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-4926000	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	6071000	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18000	USD
CY2005	us-gaap	Stockholders Equity Other StockholdersEquityOther	-141000	USD
CY2007	adhxf	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	694000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	493000	USD
CY2003	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1058000	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1983000	USD
CY1999	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1615000	USD
CY2000	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	793000	USD
CY2005	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	53000	USD
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-13871000	USD
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-16440000	USD
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-13357000	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-13600000	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-3012000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-7824000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	4685000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-5163000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	1845000	USD
CY1998	us-gaap	Net Income Loss NetIncomeLoss	-398000	USD
CY1999	us-gaap	Net Income Loss NetIncomeLoss	-958000	USD
CY2000	us-gaap	Net Income Loss NetIncomeLoss	-1605000	USD
CY2001	us-gaap	Net Income Loss NetIncomeLoss	-2524000	USD
CY2002	us-gaap	Net Income Loss NetIncomeLoss	-3732000	USD
CY2003	us-gaap	Net Income Loss NetIncomeLoss	-17795000	USD
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-6872000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6594000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37000	USD
CY2005Q4	us-gaap	Stockholders Equity StockholdersEquity	11077000	USD
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	1268000	USD
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	14148000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	3053000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	406000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-120000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-4957000	USD
CY1998Q2	us-gaap	Stockholders Equity StockholdersEquity	-435000	USD
CY1999Q2	us-gaap	Stockholders Equity StockholdersEquity	242000	USD
CY2000Q2	us-gaap	Stockholders Equity StockholdersEquity	47000	USD
CY2001Q2	us-gaap	Stockholders Equity StockholdersEquity	9792000	USD
CY2003Q2	us-gaap	Stockholders Equity StockholdersEquity	698000	USD
CY2004Q2	us-gaap	Stockholders Equity StockholdersEquity	20454000	USD
CY1997Q2	us-gaap	Stockholders Equity StockholdersEquity	-37000	USD
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Trading Symbol TradingSymbol	ADHXF
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29307618	shares
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	ADHEREX TECHNOLOGIES INC
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001211583
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5729000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3207000	USD
CY2014Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	116000	USD
CY2013Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	54000	USD
CY2013Q1	adhxf	Issue Of Convertible Common Stock As Per Licence Agreement IssueOfConvertibleCommonStockAsPerLicenceAgreement	13902000	shares
CY2013Q1	adhxf	Expired Convertible Common Stock ExpiredConvertibleCommonStock	21250000	shares
CY2013Q1	adhxf	Milestone Payment Fees MilestonePaymentFees	100000	USD
CY2014Q1	us-gaap	Contractual Obligation ContractualObligation	67000	USD
CY2014Q1	adhxf	Contractual Obligations Current ContractualObligationsCurrent	67000	USD
CY2014Q1	adhxf	Contractual Obligation Due Year One Through Year Three ContractualObligationDueYearOneThroughYearThree	0	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	825974000	shares
CY2014Q1	adhxf	Description Of Stock Options Expected Vest DescriptionOfStockOptionsExpectedVest	Such options shall vest: (i) as to 200,000 Common Shares, on the date of grant; and (ii) as to 200,000 Common Shares, upon and subject to orphan drug approval of STS in the EU, provided that they then remain on the Board at the time of such approval and that they have played a vital or precipitating part in obtaining such EU orphan drug designation, as reasonably determined by non-interested Board members. If the vesting conditions referred to in (ii) above have not occurred by May 31, 2016, the option to acquire the 200,000 common shares referred to in (ii) above shall be terminated and of no further force or effect.

Files In Submission

Name	View Source	Status
0001144204-14-031132-index-headers.html	Edgar Link	pending
0001144204-14-031132-index.html	Edgar Link	pending
0001144204-14-031132.txt	Edgar Link	pending
0001144204-14-031132-xbrl.zip	Edgar Link	pending
adhxf-20140331.xml	Edgar Link	completed
adhxf-20140331.xsd	Edgar Link	pending
adhxf-20140331_cal.xml	Edgar Link	unprocessable
adhxf-20140331_def.xml	Edgar Link	unprocessable
adhxf-20140331_lab.xml	Edgar Link	unprocessable
adhxf-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v377500_10q.htm	Edgar Link	pending
v377500_ex31-1.htm	Edgar Link	pending
v377500_ex31-2.htm	Edgar Link	pending
v377500_ex32-1.htm	Edgar Link	pending
v377500_ex99-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc

2014 Q1 Form 10-Q Financial Statement

#000114420414031132 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FENC FENNEC PHARMACEUTICALS INC. Stock $fenc

2014 Q1 Form 10-Q Financial Statement

#000114420414031132 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc